Mathieu Moreau
Overview
Explore the profile of Mathieu Moreau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dias A, Burgy O, Moreau M, Goncalves V, Pommerolle L, Douhard R, et al.
Theranostics
. 2025 Feb;
15(6):2092-2103.
PMID: 39990206
Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by an excessive collagen deposition ultimately leading to tissue stiffening and functional decline. Beyond IPF, other progressive pulmonary fibrosis are often...
2.
Saou S, Moreau M, Lioret V, Berrou A, Hernandez-Garcia M, Decreau R
Nanoscale
. 2025 Feb;
17(9):5429-5437.
PMID: 39898373
Liposomes used for the study were prepared and carefully characterized multiple times until all batches indicated the same characterization data (DOPC/cholesterol derivative (1 : 1.15 mol%), 14 mg(DOPC) mL, =...
3.
Bellaye P, Dias A, Vrigneaud J, Bouchard A, Moreau M, Petitot C, et al.
Heliyon
. 2024 Nov;
10(20):e39543.
PMID: 39498075
Purpose: Radiation therapy (RT) exerts its anti-tumour efficacy by inducing direct damage to cancer cells but also through modification of the tumour microenvironment (TME) by inducing immunogenic antitumor response. Conversely,...
4.
Grefve J, Soderkvist K, Gunnlaugsson A, Sandgren K, Jonsson J, Keeratijarut Lindberg A, et al.
Phys Imaging Radiat Oncol
. 2024 Sep;
31:100633.
PMID: 39286772
Background And Purpose: Dose escalation in external radiotherapy of prostate cancer shows promising results in terms of biochemical disease-free survival. Boost volume delineation guidelines are sparse which may cause high...
5.
Zarei M, Wallsten E, Grefve J, Soderkvist K, Gunnlaugsson A, Sandgren K, et al.
Acta Oncol
. 2024 Jun;
63:503-510.
PMID: 38912830
Background: The delineation of intraprostatic lesions is vital for correct delivery of focal radiotherapy boost in patients with prostate cancer (PC). Errors in the delineation could translate into reduced tumour...
6.
Vizier R, Adumeau P, Moreau M, Goncalves V, Denat F
Bioconjug Chem
. 2024 Apr;
35(5):633-637.
PMID: 38656148
Zirconium-89 is the most widely used radioisotope for immunoPET because its physical half-life (78.2 h) suits the one of antibodies. Desferrioxamine B (DFO) is the standard chelator for the complexation...
7.
Privat M, Massot A, Hermetet F, Al Sabea H, Racoeur C, Mabrouk N, et al.
J Med Chem
. 2024 Jan;
67(3):2188-2201.
PMID: 38270503
Detection of biomarkers to diagnose, treat, and predict the efficacy of cancer therapies is a major clinical challenge. Currently, biomarkers such as PD-L1 are commonly detected from biopsies, but this...
8.
Lioret V, Bellaye P, Bernhard Y, Moreau M, Guillemin M, Drouet C, et al.
Photodiagnosis Photodyn Ther
. 2023 Oct;
44:103816.
PMID: 37783257
Context: Old-generation photosensitizers are minimally used in current photodynamic therapy (PDT) because they absorb in the UV/blue/green region of the spectrum where biological tissues are generally highly absorbing. The UV/blue...
9.
Vizier R, Garnier A, Dias A, Moreau M, Claron M, Collin B, et al.
Mol Pharm
. 2023 Jun;
20(7):3613-3622.
PMID: 37307296
Noninvasive imaging of idiopathic pulmonary fibrosis (IPF) remains a challenge. The aim of this study was to develop an antibody-based radiotracer targeting Lysyl Oxidase-like 2 (LOXL2), an enzyme involved in...
10.
Privat M, Bellaye P, Chazeau E, Racoeur C, Adumeau P, Vivier D, et al.
Bioconjug Chem
. 2023 Mar;
PMID: 36971386
Among all approaches in molecular imaging, the combination of near-infrared fluorescence imaging (NIRF) with radioisotopic imaging (PET or SPECT) allows one to benefit from the advantages of each of the...